

5<sup>th</sup> November 2019

## Update on First Fludrocortisone Study in Humans with dry Age-Related Macular Degeneration.

Eye Co is very pleased to advise that a Phase Ib human safety study with its lead compound **Fludrocortisone Acetate** in the treatment of **dry Age-Related Macular Degeneration (d-AMD)** is providing highly promising results.

Early indications show that Fludrocortisone **does not result in increased intraocular pressure (IOP)** in the human eye commonly observed with other intra ocular agents including anti-VEGF's. This is consistent with pre-clinical data. Furthermore, an increase in visual acuity was observed in one patient.

*Fludrocortisone Acetate* is a potential breakthrough treatment for Geographic Atrophy (GA) associated with the dry form of AMD. This will be the first time this drug is being used in humans with retinal disease in this otherwise untreatable condition.

There are also substantial pre-clinical data indicating that this drug will be effective in other inflammatory/wet retinal diseases.

d-AMD represents a substantial market opportunity as there is currently no registered or available effective treatment for this condition globally. This condition will afflict over 100 million people in the major pharmaceutical markets over the next 10 years.

Professor Philip Penfold, Eye Co's Chief Scientist, said: "We are pleased with the progress being made with this drug in a clinical setting."

The study is due to conclude in mid-2020.

Your sincerely



Peter Abrahamson, FAICD  
Managing Director